WHO世界卫生组织：2024年优化艾滋病毒感染者的二线和三线抗逆转录病毒治疗报告（英文版）

This report summarizes the clinical evidence, key challenges and research gaps for optimizing second-line and third-line antiretroviral therapy (ART) regimens included in current WHO treatment guidelines as well as the advances in the management of adverse drug reactions and emerging drug resistance to these ART regimens from a public health perspective. The report reviewed the latest data on the potential use of darunavir/ritonavir as a preferred protease inhibitor option in second-line and